Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
Portfolio Pulse from Vandana Singh
GSK Plc announced a cap on out-of-pocket costs for its asthma and COPD medicines at $35 per month, starting January 1, 2025. This follows a similar move by AstraZeneca Plc, and both are in response to criticism from the HELP Committee over high inhaler prices in the U.S. compared to other countries. Teva Pharmaceutical Industries Limited was also mentioned as one of the companies criticized for high inhaler prices. GSK shares saw a slight increase in premarket trading.
March 21, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Teva was criticized alongside GSK and AstraZeneca for high inhaler prices in the U.S. compared to other countries, impacting its public image.
Teva's inclusion in the criticism over high inhaler prices could negatively affect its public image and potentially its stock price, as it may face pressure to implement similar cost-capping measures.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
AstraZeneca announced a similar cap on inhaler costs, setting a $35/month limit for eligible patients, in response to criticism over high prices.
AstraZeneca's move to cap inhaler costs is likely to be viewed positively by the market, enhancing its reputation and potentially leading to increased demand for its respiratory medications.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
GSK caps out-of-pocket inhaler costs at $35/month, aiming to reduce patient expenses for asthma and COPD medications. Shares slightly up in premarket trading.
GSK's decision to cap inhaler costs could improve its public image and potentially increase sales volume by making treatments more affordable. The slight premarket share increase suggests a positive market reaction.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90